secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001549595-23-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix licenses IRAK4 degrader to Gilead for $20M; Q1 net loss $40.7M
--------------------------------------------------------------------

- Gilead exercised option to license NX-0479/GS-6791, triggering $20M payment; up to $425M in milestones plus tiered royalties up to low double-digits.
- Q1 collaboration revenue $12.7M (up from $9.6M); net loss $40.7M ($0.75/share) vs $42.5M ($0.95) YoY.
- Cash and marketable securities $325.6M as of Feb 28, 2023, down from $373.0M at Nov 30, 2022.
- Achieved $7.5M in research milestones from Gilead ($6.5M) and Sanofi ($1.0M) during the quarter.
- Anticipates presenting Phase 1 clinical data for NX-2127, NX-5948, and NX-1607 in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/0001549595-23-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000030/nrix-20230413.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer